Have a personal or library account? Click to login
Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs Cover

Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs

Seminars in Cardiovascular Medicine
Volume 24 (2018): Issue 1 (August 2018)
By: Jonas Černeckis,  Austėja Samuolytė,  Greta Baltušytė,  Rugilė Ivanickaitė and  Kristijonas Puteikis  
Open Access
|Sep 2018

References

  1. [1] European Medicines Agency. New safety advice for diclofenac 2013;2013.
    Search in Google ScholarBack to article
  2. [2] U. S. Food and Drug Administration. FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015.
    Search in Google ScholarBack to article
  3. [3] National Institute for Health and Care Excellence. Non-steroidal anti-inflammatory drugs. NICE Guideline (KTT13) 2017.
    Search in Google ScholarBack to article
  4. [4] PLLC “SoftDent”. Drug sales data 2015-2017. 2017.
    Search in Google ScholarBack to article
  5. [5] Borazan NH, Furst DE. Nonsteroidal Anti-Inflamatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Katzung BG, Trevor AJ, editors. Basic & Clinical Pharmacology, 13th Ed. McGraw-Hill Medical; 2015; p. 618-641.
    Search in Google ScholarBack to article
  6. [6] Mullan J,Weston KM, Bonney A, Burns P, Mullan J, Rudd R. Consumer knowledge about over-the-counter NSAIDs: they don’t know what they don’t know. Aust Nz J Publ Heal 2017;41(2):210-214.10.1111/1753-6405.12589
    Search in Google ScholarBack to article
  7. [7] Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag C 2013; 9(14 Suppl):s267-72.
    Search in Google ScholarBack to article
  8. [8] Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediat Inflamm 2013;2013.10.1155/2013/258209
    Search in Google ScholarBack to article
  9. [9] Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet 2013;382(9894):769-779.10.1016/S0140-6736(13)60900-9
    Search in Google ScholarBack to article
  10. [10] Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Safety 2014;37(11):897.10.1007/s40264-014-0207-2420676725079141
    Search in Google ScholarBack to article
  11. [11] Perazella MA, Luciano RL. Review of select causes of druginduced AKI. Expert Rev Clin Phar 2015;8(4):367-371.10.1586/17512433.2015.104548926109096
    Search in Google ScholarBack to article
  12. [12] Grosser T, Ricciotti E, FitzGerald GA. The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. Trends Pharmacol Sci 2017;38(8):733-748.10.1016/j.tips.2017.05.008567655628651847
    Search in Google ScholarBack to article
  13. [13] Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 2016;42(1):27-38.10.1111/jcpt.1248428019014
    Search in Google ScholarBack to article
  14. [14] Anwar A, Anwar IJ, Delafontaine P. Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends Cardiovas Med 2015;25(8):726-735.10.1016/j.tcm.2015.03.00625956433
    Search in Google ScholarBack to article
  15. [15] Patrono C. Cardiovascular effects of nonsteroidal antiinflammatory drugs. Curr Cardiol Rep 2016;18(3):25-25.10.1007/s11886-016-0702-426841787
    Search in Google ScholarBack to article
  16. [16] Ungprasert P. NSAIDs and cardiovascular disease: time to say no to diclofenac. Intern Emerg Med 2016;11(1):1.10.1007/s11739-015-1295-426306711
    Search in Google ScholarBack to article
  17. [17] Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy 2015;35(5):520-535.10.1002/phar.158425940579
    Search in Google ScholarBack to article
  18. [18] Lapi F, Piccinni C, et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016;11(1):49.10.1007/s11739-015-1288-326271463
    Search in Google ScholarBack to article
  19. [19] McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006;296(13):1633-44.10.1001/jama.296.13.jrv6001116968831
    Search in Google ScholarBack to article
  20. [20] Varas-Lorenzo C, Riera-Guardia N, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidem Dr S 2011;20(12):1225-1236.10.1002/pds.222721971833
    Search in Google ScholarBack to article
  21. [21] Medicines and Healthcare products Regulatory Agency. Diclofenac: new contraindications and warnings. 2013.
    Search in Google ScholarBack to article
  22. [22] McGettigan P, Henry D. Use of non-steroidal antiinflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10(2):e1001388.10.1371/journal.pmed.1001388357055423424288
    Search in Google ScholarBack to article
  23. [23] van Walsem A, Pandhi S, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther 2015;17(1):66.10.1186/s13075-015-0554-0441179325879879
    Search in Google ScholarBack to article
  24. [24] Kearney PM, Baigent C, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-1308.10.1136/bmj.332.7553.1302147304816740558
    Search in Google ScholarBack to article
  25. [25] Trelle S, Reichenbach S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.10.1136/bmj.c7086301923821224324
    Search in Google ScholarBack to article
  26. [26] McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8(9):e1001098.10.1371/journal.pmed.1001098318123021980265
    Search in Google ScholarBack to article
  27. [27] Arfè A, Scotti L, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.10.1136/bmj.i485727682515
    Search in Google ScholarBack to article
  28. [28] Bally M, Dendukuri N, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.10.1136/bmj.j1909542354628487435
    Search in Google ScholarBack to article
  29. [29] Nissen SE, Yeomans ND, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New Engl J Med 2016;375:2519-2529.10.1056/NEJMoa161159327959716
    Search in Google ScholarBack to article
  30. [30] Sondergaard KB, Weeke P, et al. Non-steroidal antiinflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J-Card Pharm 2016;3(2):100-107.10.1093/ehjcvp/pvw041
    Search in Google ScholarBack to article
  31. [31] European Medicines Agency. Updated advice on use of high-dose ibuprofen 2015. 2015.
    Search in Google ScholarBack to article
  32. [32] European Medicines Agency. PRAC recommends updating advice on use of high-dose ibuprofen. 2015.
    Search in Google ScholarBack to article
  33. [33] National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. NICE Guideline (CG183) 2014.
    Search in Google ScholarBack to article
  34. [34] National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management. NICE Guideline (NG38) 2016;1.1.6:4.
    Search in Google ScholarBack to article
  35. [35] National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management. NICE Guideline (NG59) 2016.
    Search in Google ScholarBack to article
  36. [36] National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. NICE Guideline (CG182) 2015.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/semcard-2018-0003 | Journal eISSN: 1822-7767
Journal RSS Feed
Language: English
Page range: 16 - 21
Submitted on: Sep 5, 2017
|
Accepted on: Feb 14, 2018
|
Published on: Sep 1, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
NSAID,
cardiovascular risk,
diclofenac safety,
naproxen,
NSAID guidelines
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Cardiology

© 2018 Jonas Černeckis, Austėja Samuolytė, Greta Baltušytė, Rugilė Ivanickaitė, Kristijonas Puteikis, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 24 (2018): Issue 1 (August 2018)Next article